Clinical-stage regenerative medicine company Cyrano Therapeutics Inc announced on Tuesday that it is providing clinical material to support an investigator-led feasibility study assessing CYR-064 in Parkinson's disease patients.

CYR-064, Cyrano Therapeutics' lead product, is also currently being evaluated for the treatment of patients suffering from hyposmia and anosmia with various causes, including post-viral hyposmia, in a 150-subject, randomised placebo-controlled Phase 2 clinical study being conducted at 14 sites in the United States. Top-line data from this trial is expected in the second half of 2025.

The new study, titled 'A Single Arm Feasibility Study for the Treatment of Parkinson's Disease Related Hyposmia Using CYR-064 Theophylline Spray' (Protocol No. CYR-064-12), is being conducted under the leadership of David Silvers, MD, FAAN, in Palm Beach Gardens, Florida. The 32-week study will enrol approximately 15-20 adult patients aged 18 to 80 years with moderate to severe hyposmia due to Parkinson's disease. The study protocol includes a 24-week treatment period during which patients will receive a twice daily dose of CYR-064 through two sprays per nostril.

The purpose of the study is to evaluate the feasibility, safety and potential effectiveness of CYR-064 in improving the sense of smell and taste perception in affected individuals.